首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   32326篇
  免费   2411篇
  国内免费   390篇
耳鼻咽喉   354篇
儿科学   901篇
妇产科学   759篇
基础医学   4146篇
口腔科学   728篇
临床医学   3372篇
内科学   5924篇
皮肤病学   709篇
神经病学   2817篇
特种医学   1046篇
外国民族医学   3篇
外科学   4210篇
综合类   1235篇
一般理论   28篇
预防医学   2727篇
眼科学   785篇
药学   2355篇
  5篇
中国医学   291篇
肿瘤学   2732篇
  2024年   140篇
  2023年   231篇
  2022年   468篇
  2021年   697篇
  2020年   467篇
  2019年   647篇
  2018年   651篇
  2017年   563篇
  2016年   576篇
  2015年   749篇
  2014年   955篇
  2013年   1379篇
  2012年   1952篇
  2011年   2041篇
  2010年   1225篇
  2009年   1084篇
  2008年   1793篇
  2007年   1828篇
  2006年   1807篇
  2005年   1739篇
  2004年   1576篇
  2003年   1478篇
  2002年   1378篇
  2001年   650篇
  2000年   601篇
  1999年   622篇
  1998年   380篇
  1997年   335篇
  1996年   330篇
  1995年   306篇
  1994年   260篇
  1993年   261篇
  1992年   391篇
  1991年   377篇
  1990年   368篇
  1989年   339篇
  1988年   292篇
  1987年   239篇
  1986年   292篇
  1985年   264篇
  1984年   248篇
  1983年   223篇
  1982年   246篇
  1981年   228篇
  1980年   176篇
  1979年   209篇
  1978年   147篇
  1977年   149篇
  1976年   139篇
  1974年   163篇
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
61.
目的:骨髓间质干细胞体外诱导和非诱导培养向心肌细胞分化的结果的对比。方法:实验于2003-03/2004-12在阜外心血管病医院中心实验室完成。①分离犬骨髓间质干细胞。②于体外培养,应用不同浓度(0,6,8,10,12,14,20μmol/L)的5-氮胞苷定向诱导并连续传代培养4周,未诱导的细胞培养8周。③进行细胞形态学、细胞免疫组织化学、透射电镜鉴定。结果:(D骨髓间质于细胞于5-氮胞苷诱导培养2周时,α-肌动蛋白、TroponinI染色阴性;4周时,α-肌动蛋白染色阳性,Troponin I阴性;电镜下可见肌丝结构,其中8mmol/L 5-氮胞苷诱导的间质干细胞肌丝结构排列较规则。②骨髓间质干细胞非诱导培养8周时,α-肌动蛋白染色阳性,Troponin I阴性,电镜下亦可见肌丝结构形成;而培养4周时全部为阴性。结论:骨髓间质干细胞经5-氮胞苷诱导培养4周及未诱导连续培养8周均可定向转化为具有肌丝结构的肌样细胞,而非心肌样细胞。  相似文献   
62.
63.

Background

The Cancer and Leukemia Group B 9,343 demonstrated that postoperative radiation can be safely omitted in women ≥70 years who underwent breast-conserving therapy for clinical stage I (T1N0M0) estrogen receptor positive breast cancer treated with antihormonal therapy. Whether such results are observed in real-world population is unknown. In this hospital-based data, we report the survival outcomes of patients who received adjuvant radiation therapy versus those who did not.

Methods

Using the National Cancer Data Base, we evaluated a cohort of 47,358 women with newly diagnosed breast cancer between 2004 and 2011 who underwent a lumpectomy and antihormonal therapy with the following criteria: age ≥70 years, clinical stage I, estrogen receptor positive, and negative margins. Patients were stratified into 2 groups: (1) radiation therapy and (2) no radiation therapy. Propensity score matching was used to compensate for differences in demographic and clinical characteristics of the patients. Univariate and multivariable survival analysis were employed to determine factors associated with overall survival.

Results

The 5-year overall survival after propensity score matching was 87.2% for radiation therapy and 79.4% for no radiation therapy (P?<?.0001). The median survival time was 113.7 months for radiation therapy and 105.2 months for no radiation therapy. After adjusting for sociodemographic and clinical factors, the risk of overall deaths was significantly higher for those not receiving radiation therapy (hazard ratio?=?1.66; 95% confidence interval, 1.54–1.79). Other significant adjusted predictors (P?<?.05) of poor overall survival were, advanced age, comprehensive community cancer program, facility location, poorly differentiated tumor, and high comorbidity index.

Conclusion

Patients who received radiation therapy had better survival outcomes than those who did not, revealing discordance between results of randomized trials and real-world setting.  相似文献   
64.
65.
66.
67.

Context

Salvage radiotherapy (SRT) is a standard of care for men who recur postprostatectomy, and recent randomized trials have assessed the benefit and toxicity of adding hormone therapy (HT) to SRT with differing results.

Objective

To perform a systematic review of randomized phase III trials of the use of SRT ± HT and generate a framework for the use of HT with SRT.

Evidence acquisition

Systematic literature searches were conducted on February 15, 2017 in three databases (MEDLINE [via PubMed], EMBASE, and ClinicalTrials.gov) for human-only randomized clinical trials from January 30, 1990, through January 30, 2017. Only two randomized trials met all inclusion criteria.

Evidence synthesis

Overall survival benefits from HT were found in one trial, which was limited to when follow-up extended to ≥10 yr, pre-SRT prostate-specific antigen (PSA) ≥0.7 ng/ml, or when higher Gleason grade or positive margins were present. Both trials demonstrated a benefit from HT in men with higher pre-SRT PSAs. Three prognostic factors appeared to discriminate improvements in meaningful clinical endpoints (eg, distant metastasis or survival): pre-SRT PSA, Gleason score, and margin status. Two years of bicalutamide monotherapy resulted in higher rates of gynecomastia with a trend for worse survival when given in favorable risk patients, and 6 mo of luteinizing hormone–releasing hormone agonist therapy resulted in higher rates of hot flashes and long-term hypertension.

Conclusions

Similar to the selective use of HT with radiotherapy in localized prostate cancer, not all patients appear to derive a meaningful benefit from HT with SRT. Patient, tumor, and treatment factors must be considered when recommending the use of HT with SRT. Knowledge gaps exist in the level 1 data regarding the optimal duration and type of HT, as well as the ability to use predictive biomarkers to personalize the use of HT with SRT. Important clinical trials (RADICALS and NRG GU-006) are aimed to answer these questions.

Patient summary

In this report, we performed a systematic review of the literature to determine the benefit and harm of adding hormone therapy to salvage radiotherapy (SRT) for recurrent prostate cancer. We found that the benefit of hormone therapy varied by important prognostic factors, including pre-SRT prostate-specific antigen, Gleason grade, and surgical margin status. Our group then developed a framework on how best to utilize hormone therapy with SRT.  相似文献   
68.
69.
70.

Background

The effectiveness of trauma systems in decreasing injury mortality and morbidity has been well demonstrated. However, little is known about which components contribute to their effectiveness. We aimed to systematically review the evidence of the impact of trauma system components on clinically important injury outcomes.

Methods

We searched MEDLINE, EMBASE, Cochrane CENTRAL, and BIOSIS/Web of Knowledge, gray literature and trauma association Web sites to identify studies evaluating the association between at least one trauma system component and injury outcome. We calculated pooled effect estimates using inverse-variance random-effects models. We evaluated quality of evidence using GRADE criteria.

Results

We screened 15,974 records, retaining 41 studies for qualitative synthesis and 19 for meta-analysis. Two recommended trauma system components were associated with reduced odds of mortality: inclusive design (odds ratio [OR] = 0.72 [0.65–0.80]) and helicopter transport (OR = 0.70 [0.55–0.88]). Pre-Hospital Advanced Trauma Life Support was associated with a significant reduction in hospital days (mean difference [MD] = 5.7 [4.4–7.0]) but a nonsignificant reduction in mortality (OR = 0.78 [0.44–1.39]). Population density of surgeons was associated with a nonsignificant decrease in mortality (MD = 0.58 [?0.22 to 1.39]). Trauma system maturity was associated with a significant reduction in mortality (OR = 0.76 [0.68–0.85]). Quality of evidence was low or very low for mortality and healthcare utilization.

Conclusions

This review offers low-quality evidence for the effectiveness of an inclusive design and trauma system maturity and very-low-quality evidence for helicopter transport in reducing injury mortality. Further research should evaluate other recommended components of trauma systems and non-fatal outcomes and explore the impact of system component interactions.
  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号